Cue Biopharma is trading 13.6% lower at $17.14 amid broad market and biotech weakness. - No fresh company-specific announcement explaining the November 5 decline surfaced in the search; the latest identified company news was positive CUE-221 Phase 2 results in September. - Technology and growth stocks are under pressure amid AI-regulation concerns and broader risk-off sentiment. - Biotech is also weak; supplied sector context shows XBI down 5.19%, pointing to market and sector pressure rather than a company-specific catalyst.